Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
NRX Pharmaceuticals, Inc. (NRXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC",
"Opinion of Haynes and Boone, LLP"
08/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/28/2023 8-K Quarterly results
06/08/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
06/07/2023 8-K/A Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Stat...
Docs: "COMMON STOCK PURCHASE WARRANT NRX Pharmaceuticals, Inc. Warrant Shares: _______ Initial Exercise Date: December 6, 2023 Issue Date: June 6, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ______, 2023 1 and on or prior to 5:00 p.m. on ____, 2028 2 but not thereafter, to subscribe for and purchase from NRX Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .          &#8...",
"Holder of the Preferred Investment Options to Purchase Common Stock",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between NRX Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Prefunded Warrants and Prefunded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants and the Common Warrant Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of th...",
"LOCK-UP AGREEMENT",
"NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering"
06/06/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "COMMON STOCK PURCHASE WARRANT NRX Pharmaceuticals, Inc. Warrant Shares: _______ Initial Exercise Date: December 6, 2023 Issue Date: June 6, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ______, 2023 1 and on or prior to 5:00 p.m. on ____, 2028 2 but not thereafter, to subscribe for and purchase from NRX Pharmaceuticals, Inc., a Delaware corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .          &#8...",
"Holder of the Preferred Investment Options to Purchase Common Stock",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of June 6, 2023, between NRX Pharmaceuticals, Inc., a Delaware corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares, the Prefunded Warrants and Prefunded Warrant Shares and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Common Warrants and the Common Warrant Shares, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of th...",
"LOCK-UP AGREEMENT",
"NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering"
05/26/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/21/2023 8-K Quarterly results
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 8-K Quarterly results
03/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/13/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
03/10/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
03/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Form of Investor Warrant",
"Opinion of Kirkland & Ellis LLP",
"Form of Securities Purchase Agreement",
"NRx Pharmaceuticals Announces Close of $2.9 Million Registered Direct Offering · NRx Pharmaceuticals received approximately $2.9 million in cash from existing investors. · Offering will assist the Company to initiate its National Treatment Protocol and Safety Database for NRX-101 for Treatment-Resistant Bipolar Depression with Risk of Self Harm. RADNOR, Pa., March 9, 2023 /PRNewswire/ — NRx Pharmaceuticals, Inc. , a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it consummated an offering of 3,766,666 shares of common stock and 3,766,666 warrants to purchase common stock at a combined purchase price of $0.75 per share of common stock and associated warrant. The shares of common stock purchased in the offering are subject to restrict..."
02/24/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
02/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 5 Javitt Jonathan C (10% Owner) has filed a Form 5 on NRX Pharmaceuticals, Inc.
02/13/2023 8-K Quarterly results
02/02/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
01/10/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
12/23/2022 PRE 14A Form PRE 14A - Other preliminary proxy statements:
12/02/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
Docs: "Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements",
"NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update"
11/09/2022 8-K Quarterly results
09/13/2022 SC 13D Javitt Daniel C. reports a 14.6% stake in NRX Pharmaceuticals, Inc.
08/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Release of an ad hoc announcement pursuant to Art. 53 LR RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION"
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/12/2022 10-Q/A Quarterly Report for the period ended September 30, 2021 [amend]
08/12/2022 10-Q/A Quarterly Report for the period ended June 30, 2021 [amend]
08/12/2022 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy